Response rate (%) ITd induction On protocol placebo On protocol ixazomib N=143 N=39 N=39

Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.. Consensus-based recommendations for

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide

Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.. Tavazzi L, Maggioni

Baseline characteristics of patients, according to randomized assignment to n-3 PUFA or placebo included in intention to treat analysis. Continuous variables are given as mean±SD

Therefore, the aim of this study is to evaluate the acute effects of PBMT on systemic levels of inflammatory mediators (TNF-a, IL-6 and PGE 2 ) and pain intensity in patients

Patients will be randomised to orally administrated clonidine or placebo until delirium free (by DSM-5 criteria) or no subsyndromal delirium for 2 days, or after a maximum of 7

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide

Antirheumatic therapy is not associated with changes in circulating N-terminal pro-brain natriuretic peptide levels in patients with autoimmune arthritis..